This clinical trial is focused on studying a condition known as Diabetic Peripheral Neuropathy, which is a type of nerve damage that can occur in people with diabetes, leading to pain and discomfort in the limbs. The study will evaluate a new treatment called LY3556050, which is taken in the form of a capsule. This medication is being tested to see if it can help reduce the pain intensity associated with this condition.

The purpose of the study is to determine if LY3556050 is more effective than a placebo in managing pain for individuals with Diabetic Peripheral Neuropathy. Participants in the study will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This approach is known as a double-blind study, which helps ensure the results are unbiased.

Throughout the study, participants will take the medication or placebo orally, and their pain levels will be monitored over time. The study aims to find out if different doses of LY3556050 can provide better pain relief compared to the placebo. The trial is expected to continue until early 2025, with the goal of improving treatment options for those suffering from pain due to Diabetic Peripheral Neuropathy.